We are live on ! Find out more
KNTE

Kinnate Biopharma Inc. Common Stock
KNTE

Delisted

KNTE was delisted on the 2nd of April, 2024.

Back to rankings

72 hedge funds and large institutions have $121M invested in Kinnate Biopharma Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 12 increasing their positions, 23 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,100% more call options, than puts

Call options by funds: $72K | Put options by funds: $6K

1% more funds holding

Funds holding: 71 → 72 (+1)

4% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 28

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

48% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 23

55% less capital invested

Capital invested by funds: $270M → $121M (-$149M)

Holders
72
Holders Change
+1
Holders Change %
+1.41%
% of All Funds
1.13%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
29
Increased
12
Reduced
23
Closed
28
Calls
$72K
Puts
$6K
Net Calls
+$66K
Net Calls Change
-$137K

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$11M
2
FCMV
Foresite Capital Management V
California
+$5.98M
3
Millennium Management
Millennium Management
New York
+$3.48M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.55M
5
Renaissance Technologies
Renaissance Technologies
New York
+$876K

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$26.7M
2
APM
Avidity Partners Management
Texas
-$7.25M
3
WP
Woodline Partners
California
-$6.81M
4
BlackRock
BlackRock
New York
-$5.99M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
FCMI
1
Foresite Capital Management IV
California
$29.3M – – –
O
2
OrbiMed
New York
$24.3M +$11M +2,866,100 +56%
FCMV
3
Foresite Capital Management V
California
$10.7M +$5.98M +1,550,956 +79%
NI
4
Nextech Invest
Switzerland
$7.06M – – –
VVA
5
Vida Ventures Advisors
Massachusetts
$6.69M – – –
LCM
6
Lynx1 Capital Management
Puerto Rico
$6.21M -$638K -165,514 -7%
Viking Global Investors
7
Viking Global Investors
Connecticut
$5.52M – – –
Citadel Advisors
8
Citadel Advisors
Florida
$3.29M +$49.5K +12,837 +1%
Vanguard Group
9
Vanguard Group
Pennsylvania
$3.01M -$117K -30,474 -3%
Millennium Management
10
Millennium Management
New York
$2.73M +$3.48M +902,242 New
NHAS
11
Novo Holdings A/S
Denmark
$2.47M – – –
RSCM
12
Rock Springs Capital Management
Maryland
$2.26M – – –
BlackRock
13
BlackRock
New York
$2.19M -$5.99M -1,554,107 -68%
Fidelity Investments
14
Fidelity Investments
Massachusetts
$2.04M -$3.75M -972,342 -59%
BC
15
Boxer Capital
California
$1.49M -$73.2K -19,000 -4%
HMC
16
Harvard Management Company
Massachusetts
$1.4M -$137K -35,583 -7%
Acadian Asset Management
17
Acadian Asset Management
Massachusetts
$1.3M +$1.55M +401,887 +1,390%
Renaissance Technologies
18
Renaissance Technologies
New York
$1.02M +$876K +227,300 +206%
GCP
19
GSA Capital Partners
United Kingdom
$728K +$783K +203,220 +547%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$559K -$1.01M -260,946 -59%
Goldman Sachs
21
Goldman Sachs
New York
$482K -$233K -60,512 -28%
Squarepoint
22
Squarepoint
New York
$449K +$571K +148,215 New
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$440K +$404K +104,906 +261%
Jane Street
24
Jane Street
New York
$398K +$444K +115,082 +701%
AG
25
Artal Group
Luxembourg
$379K – – –
1
2 3 4

KNTE Hedge Fund Activity: Q2 2023 in Review

72 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q2 2023, worth a combined $121M — down 55% from $270M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new KNTE positions and 28 closed out — a net gain of 1 holder — while 12 added to existing stakes and 23 trimmed.

The largest buyer was OrbiMed, adding an estimated $11M. The largest seller was RA Capital Management, exiting entirely with an estimated $26.7M sold.

  • 72 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q2 2023, up from 71 in Q1 2023.
  • Funds reported $121M of Kinnate Biopharma Inc. Common Stock stock for Q2 2023, down 55% quarter-over-quarter.
  • 29 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q2 2023 and 28 closed out, a net change of +1 holder.
  • The largest Kinnate Biopharma Inc. Common Stock buyer in Q2 2023 was OrbiMed, an estimated $11M added.
  • The largest Kinnate Biopharma Inc. Common Stock seller in Q2 2023 was RA Capital Management, an estimated $26.7M sold.

Based on aggregated 13F filings for Q2 2023.